Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. (NASDAQ: LFCR) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Sections Legal Investigation - The investigation is focused on claims made in a class action complaint filed on July 29, 2024, concerning the period from October 7, 2020, to March 19, 2024 [1] - The law firm encourages long-term stockholders who suffered losses to contact them for discussions regarding their legal rights [1][3] Allegations Against LifeCore - The complaint alleges that LifeCore made materially false and misleading statements about its business, operations, and prospects during the class period [2] - Specific allegations include: - Deficient internal controls over financial reporting [2] - Issuance of inaccurate financial statements that would require restatement [2] - Ineffective remediation efforts regarding the identified deficiencies [2] - Impaired ability to file periodic reports with the SEC in compliance with NASDAQ requirements [2] - Material overstatement of the company's financial position and prospects [2] - Public statements being materially false and misleading throughout the relevant period [2] Contact Information - Long-term stockholders with information or questions are encouraged to reach out to the law firm via email or phone [3][6]